MedTrace Logo

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

NCT01530243 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-03-02

Study results available
· View outcomes & findings →

Summary

The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.

Conditions

  • Disorder of Urinary Stent

Interventions

DRUG

Placebo

same as tolterodine and terazosin dose

DRUG

Terazosine

2 mg BID

DRUG

Tolterodine

2 mg daily

DRUG

Tolterodine + Terazosin

2mg daily and 2mg BID

Sponsors & Collaborators

  • Urmia University of Medical Sciences

    lead OTHER

Principal Investigators

  • Ali Tehranchi, Urologist · Urology department

  • Yousef Rezaei, M.D · Urmia University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530243 on ClinicalTrials.gov